Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 1,134.62 · gapped above the open, then crossed back over prior close. High/low 1,158.45 at 5:30 am ET, 1,132.60 at 3:30 pm ET.
ELI Lilly & Co
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed on prior therapy.”
FILING10-K0001790340-26-000042cik 0001790340disclosed by IMRX
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
FILING10-K0001193125-26-104547cik 0000906709disclosed by NKTR
“We exclusively license from Eli Lilly and Company ("Lilly"), rights under 26 issued patents and 1 pending patent application, all of which belong to the same patent family.”
FILING10-K0001104659-26-028566cik 0001509745disclosed by CYPH
“Lilly manufactures and supplies Adcirca for us.”
FILING10-K0001082554-26-000006cik 0001082554disclosed by UTHR
“In August 2022, we entered into a non-exclusive patent license agreement with Lilly.”
FILING10-K0001104659-26-020540cik 0001557746disclosed by ACRS
“During the years ended December 31, 2025 and 2024, we recorded $0.1 million and $0.5 million, respectively, as a reduction in R&D expense in the consolidated statement of operations and comprehensive loss as a result of the earned R&D reimbursement from Eli Lilly.”
FILING10-K0001736730-26-000016cik 0001736730disclosed by CAMP
“Through our recent acquisition of Elektrofi, Inc. ("Elektrofi"), subsequently renamed Halozyme Hypercon, Inc. ("Hypercon"), we have Hypercon collaboration and license agreements with Janssen, Lilly, and argenx.”
FILING10-K0001159036-26-000024cik 0001159036disclosed by HALO
“This decrease was primarily due to a decrease of $18.8 million, or 37%, in the legacy Quanterix business due to the macro-economic conditions impacting demand for large projects from pharmaceutical customers and the completion of an agreement with Eli Lilly and Company which generated $4.5 million of revenue in 2024.”
FILING10-K0001503274-26-000013cik 0001503274disclosed by QTRX
“In September 2022, we entered into a collaboration with Lilly under which we are responsible for the discovery and optimization of small molecule compounds addressing an immunology target.”
FILING10-K0001490978-26-000010cik 0001490978disclosed by SDGR
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
FILING10-K0000059478-26-000013cik 0000059478
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
FILING10-K0000059478-26-000013cik 0000059478
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
FILING10-K0000059478-26-000013cik 0000059478
“Our pipeline includes our Phase 2b lead program, ACR-368, also known as prexasertib, a precision oncology asset in-licensed from Eli Lilly & Company, or Lilly, that targets CHK1 and CHK2, or CHK1/2.”
FILING10-K0001193125-26-115123cik 0001781174disclosed by ACRV
“For instance, we entered into clinical trial collaboration and supply agreements with Eli Lilly, pursuant to which our collaboration counterparties will supply doses of ramucirumab for use in certain clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182disclosed by ALXO
“Abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company ("Lilly") (the "Lilly License Agreement"), as well as an agreement under which AlmataBio, Inc. ("AlmataBio") purchased rights to the compound from Leap Therapeutics, Inc. ("Leap" and the "Leap Agreement").”
FILING10-K0001534120-26-000011cik 0001534120disclosed by AVTX
“Sales of Emgality, a medicine for the preventive treatment of migraine, increased 63% for the year ended December 31, 2025, compared to 2024, as a result of our acquisition of the distribution and promotion rights from Lilly in 2024 in certain markets outside of the United States.”
FILING10-K0001628280-26-011125cik 0001821825disclosed by OGN
“In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS TM for all human indications.”
FILING10-K0001628280-26-007460cik 0001347178disclosed by VNDA
“On November 7, 2025 (the "Effective Date"), our affiliates MeiraGTx Ocular UK Limited ("MeiraGTx Ocular"), MeiraGTx Limited and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthalmology.”
FILING10-K0001104659-26-036494cik 0001735438disclosed by MGTX
“In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly.”
FILING20-F0001104659-26-027342cik 0001651625disclosed by ACIU
“License and collaboration agreement with Eli Lilly On October 8, 2013, the Group entered into a licensing, co-development and commercialization agreement in China with Eli Lilly and Company ("Lilly") relating to Elunate ("Lilly Agreement"), as the China brand name for fruquintinib.”
FILING20-F0001104659-26-023822cik 0001648257disclosed by HCM
“We paid Lilly a total of $21.4 million for our share of development costs incurred through April 1, 2024.”
FILING10-K0001034842-26-000015cik 0001034842disclosed by RIGL
“In October 2023, we entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Verve Agreement, including our opt-in rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease.”
FILING10-K0001193125-26-065194cik 0001745999disclosed by BEAM
“In December 2021, we entered into a strategic collaboration agreement with Lilly (the "Lilly Collaboration Agreement").”
FILING10-K0001628280-26-016814cik 0001822462disclosed by FHTX
“we entered into a global licensing and research collaboration with Eli Lilly and Company ("Lilly") in September 2021”
FILING20-F0001104659-26-026713cik 0001612940disclosed by PRQR
Watchlist prices, news filtered to it, and its next report on your desk.
LLY (ELI Lilly & Co) has 15 disclosed suppliers and 14 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CYPH −14.73%, in healthcare.
ELI Lilly & Co has 15 disclosed suppliers and 14 disclosed customers. Each one is named in an SEC filing, either ELI Lilly & Co’s own annual report or the counterparty’s, and carries the sentence that discloses it.